Azurity Pharmaceuticals, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Azurity Pharmaceuticals, Inc. - overview
Established
1998
Location
Wilmington, MA, US
Primary Industry
Pharmaceuticals
About
CutisPharma, Inc. is a pharmaceutical company focused on developing and commercializing innovative formulations and delivery systems for dermatological and other medical conditions. CutisPharma, Inc. specializes in pharmaceutical formulations and is headquartered in Wilmington, US.
Founded in 1998, the company has undergone strategic pivots to enhance its product offerings. Richard Blackburn serves as CEO. The company has conducted a total of 4 deals, with its latest funding round being a Secondary Buyout, raising USD 69. 90 mn from NovaQuest Capital Management, matching the total amount raised to USD 69.
90 mn. CutisPharma, Inc. provides specialized pharmaceutical products aimed at dermatological applications. Its offerings include innovative formulations that improve medication delivery and patient compliance.
The company caters to healthcare providers and patients, focusing on effective treatment solutions for skin conditions and related ailments, with a strong emphasis on meeting specific medical needs. CutisPharma, Inc. generates revenue primarily through the sale of its specialized pharmaceuticals, engaging clients such as hospitals and pharmacies. Revenue is driven by a combination of direct sales and distribution agreements, facilitating access to its unique formulations in the healthcare market.
Looking ahead, CutisPharma, Inc. is focused on expanding its product line, with plans to launch new formulations within the next 12 months. The company aims to penetrate new markets in Europe and Asia by 2025, utilizing recent funding from the Secondary Buyout to support product development and market entry initiatives. Consilium Partners' acquisition of CutisPharma, Inc.
aligns with its strategic growth objectives.
Current Investors
NovaQuest Capital Management, Consilium Partners, Ampersand
Primary Industry
Pharmaceuticals
Sub Industries
Specialty Pharmaceuticals, Pharmaceutical Research & Development
Website
www.azurity.com/
Company Stage
Mature
Total Amount Raised
Subscriber access only
Azurity Pharmaceuticals, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Secondary Buyout | Completed | Azurity Pharmaceuticals, Inc. | - | ||||||||
| Add-on, Trade Sale | Announced | Arbor Pharmaceuticals, LLC | - | ||||||||
| Add-on, Trade Sale | Completed | Azurity Pharmaceuticals, Inc. | - | ||||||||
| Secondary Buyout | Completed | Azurity Pharmaceuticals, Inc. | - | ||||||||
| Growth | Completed | Azurity Pharmaceuticals, Inc. | - |
Displaying 1 - 5 of 6
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.